Weekly Oncology Highlights – Powered by ONCOassist

Your go-to digest for the latest breakthroughs in cancer care.

From breakthrough PARP/AR combo efficacy to transformative immunotherapy approvals and rare cancer strides, this week’s oncology updates spotlight how precision therapies and regulatory momentum are setting new benchmarks in survival and patient outcomes.

Leading voices. Big insights. Scroll down to watch now Dr. Akash Maniam’s Oncology Spotlight!

TALAPRO-2: Talazoparib + Enzalutamide Survival Breakthrough in mCRPC

A final overall survival analysis from the phase III TALAPRO‑2 trial showed that talazoparib plus enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer reduced risk of death by 38% (HR 0.62; p = 0.0005), extending median OS to 45.1 vs 31.1 months compared to placebo + enzalutamide.

• BRCA1/2-mutant cohort (~39%): median OS not reached vs 28.5 months (HR 0.50; p = 0.0017).
• HRR-wildtype patients: 42.4 vs 32.6 months (HR 0.73; p = 0.066).
• Radiographic PFS nearly doubled: 30.7 vs 12.3 months (HR 0.47; p < 0.0001).

Safety profile consistent: grade 3+ anemia (43%), neutropenia (20%); no new safety signals. (Reference: Fizazi et al., The Lancet, 2025 Final OS Analysis)

TEVIMBRA® (Tislelizumab) Approved in EU for Nasopharyngeal Carcinoma Based on RATIONALE-309

The European Commission approved tislelizumab (TEVIMBRA®) with gemcitabine and cisplatin as first-line therapy for metastatic/recurrent nasopharyngeal carcinoma not suitable for curative treatment.

• 48% reduction in progression/death (PFS HR 0.52; p < 0.0001); median PFS 9.2 vs 7.4 months.
• Updated OS: 45.3 vs 31.8 months.
• Safety manageable: grade 3–4 neutropenia, anemia, thrombocytopenia; no new signals. It marks TEVIMBRA’s second EU oncology approval this year, following small-cell lung cancer.

(Reference: BeOne Medicines Ltd., “European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First‑Line Treatment for Nasopharyngeal Carcinoma,” July 10, 2025)

ENGOT‑OV60/RAMP 201: Avutometinib + Defactinib in Recurrent Low‑Grade Serous Ovarian Cancer 

Results from the phase II ENGOT‑OV60/GOG‑3052/RAMP 201 study, published in JCO, showed that the oral combination of MEK inhibitor avutometinib plus FAK inhibitor defactinib induced a 31% confirmed ORR in 115 heavily pretreated patients with recurrent low-grade serous ovarian cancer (LGSOC), including complete and partial responses. Notably, KRAS-mutant tumors responded at 44%, compared with 17% in wild-type cases. Median progression-free survival was 12.9 months overall, extending to 22.0 months in the KRAS-mutant cohort versus 12.8 months in the wild-type group. The safety profile was manageable; common grade ≥3 AEs included elevated CPK (24%), diarrhea (8%), and anemia (5%), while approximately 10% discontinued due to toxicity. (Reference: Banerjee et al., JCO, 2025)

ICR Identifies New “Armour” Protein (SLC7A11) in Melanoma

The Institute of Cancer Research (UK) identified SLC7A11 as a protective protein that shields melanoma cells from oxidative stress and enhances invasive potential. Elevated SLC7A11 maintains cytoskeletal dynamics essential for amoeboid movement and metastasis. Notably, in vitro inhibition killed ~75% of melanoma cells within 72 hours, suggesting a promising therapeutic target. The researchers also caution that antioxidant supplements (e.g., glutathione) may reinforce this “armour” and should be used judiciously in melanoma patients. (Reference: ICR press release, July 15, 2025)

FDA grants Fast Track to ZEN-3694 + Abemaciclib for NUT Carcinoma

On July 14, the FDA awarded Fast Track designation to the BET inhibitor ZEN‑3694, in combination with abemaciclib, for treatment of metastatic or unresectable NUT carcinoma following prior chemotherapy. This ultra‑rare, aggressive cancer lacks approved systemic therapies. Preclinical and early clinical data support the combination’s potency, and FDA Fast Track status will facilitate expedited review via priority communication and potential accelerated approval mechanisms. (Reference: Zenith Epigenetics Ltd. press release, July 14, 2025)

This week’s Oncology Spotlight: Dr. Akash Maniam compares the Oncology Systems and Cancer Care of UK and the Caribbean

In this podcast, Dr. Akash Maniam contrasts cancer care in the UK with that in the Caribbean, spotlighting challenges from diagnostic delays to limited trial access and geographic barriers. His insights underscore the urgent need for global oncology equity, especially in low‑resource settings where systemic gaps and lack of auditing hinder outcomes.   Explore more stories & insights on ONCOassist. Your clinical edge, just a tap away.     

Join the ONCOassist oncology community, the go-to CE‑approved app for oncology professionals worldwide !

•  Access essential tools like staging systems, toxicity scoring, drug calculators, prognostic scores and NCCN regimens,all in one place .
• Stay informed with ONCOnews & ONCOvideos featuring expert insights, conference coverage and peer-tested protocols 

Download the app here:

📱IOS                                  📱Android                              💻 Webapp